Barr Pharmaceuticals
From Wikipedia, the free encyclopedia
| Barr Pharmaceuticals Inc | |
| Type | Delaware Corporation (NYSE: BRL) |
|---|---|
| Founded | New York (1970) |
| Headquarters | Woodcliff Lake, New Jersey, USA |
| Key people | Bruce Downey, CEO |
| Industry | Pharmaceuticals & Medical Devices |
| Products | Generic and Proprietary Pharmaceuticals |
| Revenue | Over $1 Billion USD fiscal year 2005 |
| Employees | 2000 |
| Website | http://www.barrlabs.com.com |
Barr Pharmaceuticals, Inc., (NYSE: BRL) is global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company headquartered in Wood Cliff Lakes, New Jersey, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Company markets more than 120 generic and 25 proprietary products in the U.S. and more than 550 products globally. Its core therapeutic categories include oncology (cancer drugs), female healthcare including hormone replacement and oral contraceptives, cardiovascular, anti-infective and psychotherapeutics. Barr Pharmaceuticals Inc. is a publicly traded company and member of the S&P 500. Bruce Downey is the CEO.
